CD274 and non-small cell lung carcinoma: Two were phase II studies: a single arm trial of Nivolumab in patients with advanced refractory squamous NSCLC [26], and the randomized phase II trial comparing Atezolizumab vs docetaxel in 287 pre-treated NSCLC patients, whose interim results have recently shown a significant benefit in favour of Atezolizumab, correlating with an increasing tumor PD-L1 expression [27].